#### RECEIVED CENTRAL FAX CENTER

MAR 0 1 2005

Atty Docket No. 016930-003712US

PTO FAX NO.:

703-872-9306

ATTENTION:

Examiner ASHEN, Jon B.

Group Art Unit 1635

# OFFICIAL COMMUNICATION FOR THE PERSONAL ATTENTION OF

### **EXAMINER ASHEN, Jon Benjamin**

#### CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Nielsen et al.

Application No. 10/086,294, filed February 28, 2002

for COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS

are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page:

Dated: 1 March 2005

10

#### Documents Attached

- 1. SB/21 Transmittal Form (1 pg)
- Response to Restriction Requirement (8 pgs)

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, CA 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

60350553 71

#### RECEIVED CENTRAL FAX CENTER

NO.073 P.2

MAR 0 1 2005

						PTO/SS/21 (33-04)		
TRANSMITTAL		Application Number	Application Number		10/086,294			
		Filing Date	Filing Date		February 28, 2002			
FORM		First Named Inventor	First Named Inventor		Nielsen, Loretta			
		Art Unit	Art Unit		1635			
(to be used for all correspondence after inlite) in		Examiner Name	Examiner Name		Ashen, Jon Benjamin			
Total Number of Pages in This Submission		Attorney Docket Num	Attomey Docket Number		016930-003712US			
ENCLOSURES (Chock all that apply)								
Fee Transm	nittal Form	Drawing(s)		<del></del>	ter Allow	ance Communication to TC		
	Attached	Licensing-related Paper	ers			mmunication to Board		
Amendment	t/Reply	Petition	, i		of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
Afte	or Final	Petition to Convert to a Provisional Application	Petition to Convert to a Provisional Application		Proprietary Information			
Affidavits/declaration(s)		Power of Attorney, Rev	Power of Attorney, Revocation Change of Correspondence Address		Status Letter			
Extension of Time Request		Terminal Disclaimer	- · · ·		Other Enclosure(s) (please identify below):			
Express Abendonment Request		Request for Refund	Request for Refund		Return Postcard			
Information Disclosure Statement		CD, Number of CD(s)	CD, Number of CD(s)					
		Landscape Tab	Landscape Table on CD					
Certified Copy of Priority Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.								
Reply to Missing Perts/ Incomplete Application								
Reply to Missing Parts under 37 CFR 1.52 or 1.53								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Name	Firm Name Townsend and Townsend and Crew LLP							
Signature Maxlu Ceul								
Printed name Nathan S. Cassell								
Date	03/01/2005		Reg. No. 42,398					
CERTIFICATE OF TRANSMISSION/MAILING								
I hereby cartify that this correspondence is being faceimile transmitted to the Patent and Trademark Office, Fax No. (703) 872-9306 on the date stated below.								
Signature Nancy Pro								
Typed or printed name Nancy Plazo		0 00	) 00		Date	03/01/2005		

60433326 v1

-MAR. 1.2005 4:50PM (TTC-PA 650-326-2422

## RECEIVED CENTRAL FAX CENTER

NO.073 P.3

MAR 0 1 2005

I hereby certify that this correspondence is being sent by facsimile to:	- PATENT
FAX NUMBER 703/872-9306	Attorney Docket No.: 016930-003712US
On1 March 2005	Customer No. 20350
TOWNSEND and TOWNSEND and CREW LLP	
By: Mancy Pego	
NANCY PIZZO	•

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen et al.

Application No.: 10/086,294

Filed: February 28, 2002

For

Combined Tumor Suppressor Gene Therapy

and Chemotherapy in the Treatment of

Neoplasms

Confirmation No. 3210

Examiner: Ashen, Jon Benjamin

T.C./Art Unit: 1635

Response to Restriction Requirement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Prior to examination of the present application, and in response to the Restriction Requirement mailed February 1, 2005, please enter and consider the following.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.